Compromised shear-dependent cleavage of type 2N von Willebrand factor variants by ADAMTS13 in the presence of factor VIII

Christopher G. Skipwith; Sandra L. Haberichter; Ashley Gehrand; X. Long Zheng

doi:10.1160/TH13-01-0053

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2013; 110(01): 202-204
DOI: 10.1160/TH13-01-0053

Letters to the Editor

Schattauer GmbH

Compromised shear-dependent cleavage of type 2N von Willebrand factor variants by ADAMTS13 in the presence of factor VIII

Christopher G. Skipwith

¹Department of Pathology and Laboratory Medicine, The Children’s Hospital of Philadelphia, Pennsylvania, USA

²The University of Pennsylvania, Philadelphia Perelman School of Medicine, Philadelphia, Pennsylvania, USA

,

Sandra L. Haberichter

³Blood Research Institute, Blood Center of Wisconsin, and Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA

,

Ashley Gehrand

³Blood Research Institute, Blood Center of Wisconsin, and Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA

,

X. Long Zheng

¹Department of Pathology and Laboratory Medicine, The Children’s Hospital of Philadelphia, Pennsylvania, USA

²The University of Pennsylvania, Philadelphia Perelman School of Medicine, Philadelphia, Pennsylvania, USA

› Author Affiliations

Abstract

Full Text

References

References
1 Gao W, Anderson PJ, Majerus EM. et al. Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease. Proc Natl Acad Sci USA 2006; 103: 19099-19004.
2 Skipwith CG, Cao W, Zheng XL. Factor VIII and platelets synergistically accelerate cleavage of von Willebrand factor by ADAMTS13 under fluid shear stress. J Biol Chem 2010; 285: 28596-28603.
3 Cao W, Sabatino DE, Altynova E. et al. Light Chain of Factor VIII Is Sufficient for Accelerating Cleavage of von Willebrand Factor by ADAMTS13 Metalloprotease. J Biol Chem 2012; 287: 32459-32466.
4 Veyradier A, Caron C, Ternisien C. et al. Validation of the first commercial ELISA for type 2N von Willebrand’s disease diagnosis. Haemophilia 2011; 17: 944-951.
5 Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev 2010; 24: 123-134.
6 Sadler JE, Budde U, Eikenboom JC. et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 04: 2103-2114.
7 Casonato A, Sartorello F, Cattini MG. et al. An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant. Blood 2003; 101: 151-156.
8 Allen S, Abuzenadah AM, Blagg JL. et al. Two novel type 2N von Willebrand disease-causing mutations that result in defective factor VIII binding, multimerization, and secretion of von Willebrand factor. Blood 2000; 95: 2000-2007.
9 Schneppenheim R, Lenk H, Obser T. et al. Recombinant expression of mutations causing von Willebrand disease type Normandy: characterization of a combined defect of factor VIII binding and multimerization. Thromb Haemost 2004; 92: 36-41.
10 Kroner PA, Friedman KD, Fahs SA. et al. Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand disease. J Biol Chem 1991; 266: 19146-19149.
11 Kroner PA, Foster PA, Fahs SA. et al. The defective interaction between von Willebrand factor and factor VIII in a patient with type 1 von Willebrand disease is caused by substitution of Arg19 and His54 in mature von Willebrand factor. Blood 1996; 87: 1013-1021.
12 Cao WJ, Krishnaswamy S, Camire RM. et al. Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13. Proc Natl Acad Sci USA 2008; 105: 7416-7421.
13 Furlan M, Robles R, Galbusera M. et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolyticuremic syndrome. N Engl J Med 1998; 339: 1578-1584.
14 Madabhushi SR, Shang C, Dayananda KM. et al. von Willebrand factor (VWF) propeptide binding to VWF D’D3 domain attenuates platelet activation and adhesion. Blood 2012; 119: 4769-4778.

Supplementary Material

Online Supplementary Material (PDF)